Strengthens balance sheet by reducing total debt by approximately 80% over the past year Strengthens balance sheet by reducing total debt by approximately 80% over the past year

Read the original post:
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity

- Two clinical stage product candidates in development for the treatment of melanoma -

See more here:
Immuneering Recognizes Melanoma Awareness Month

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

View post:
Day One Reports First Quarter 2024 Financial Results and Corporate Progress

SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company’s Chief Medical Officer and resident Key Opinion Leader, will review a selection of slides and discuss the clinical strategy for advancing the Company’s lead asset tuspetinib (TUS) in a TUS+VEN+HMA triplet drug combination for the frontline treatment of newly diagnosed AML patients.

Read more from the original source:
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

Filed Pursuant to Rule 433

Read the original:
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor

Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period

The rest is here:
T2 Biosystems Announces First Quarter 2024 Financial Results

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has agreed to grant inducement awards to (i) its newly appointed Vice President, Head of Programming & Data Operations, Xiaopeng “Jeff” Cai, MS; (ii) its newly appointed Vice President, Head of Biostatistics, Zhongwen “Justin” Tang, Ph.D.; and (iii) eleven other newly hired employees. The awards were approved by the Compensation Committee of Ocular and were made as inducements material to each individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more:
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, announced today the expansion of its strategic collaboration with the global biopharma company GSK plc (LSE/NYSE: GSK) to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB).

The rest is here:
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Read more here:
Sandoz reports first quarter 2024 sales

Conference call and webcast scheduled for May 7, 2024, at 14:00 (CET).

View original post here:
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update

May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV.

Go here to see the original:
argenx to Present at BofA Securities 2024 Health Care Conference

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Excerpt from:
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS7 May 2024 at 08.30 EEST              Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

Go here to see the original:
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

PRESS RELEASE

Follow this link:
Memo Therapeutics increases Series C financing to CHF 45 million

Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024. The full Quarterly Statement Q1 2024 can be downloaded here: https://medigene.com/investors-media/reports-presentations/. "During the first quarter of 2024, our focus remained on executing our strategic plan and advancing the development of our unique TCR-T therapies for solid tumors, such as our lead program MDG1015," said Selwyn Ho, CEO at Medigene. "While our core expertise lies in generating optimal TCRs, we are also exploring ways to broaden their application beyond TCR-T cell therapies."

Excerpt from:
Medigene AG reports Financial Results and Business Update for Q1 2024

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE26 APRIL 2024 at 11.15 EEST

See the rest here:
Composition of the Nomination Committee of Orion Corporation

Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.

Read more:
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial) at The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.

Read more:
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets.

See the original post here:
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET

The rest is here:
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024